09/09/2025
Tabuk Pharmaceuticals and Hanmi Pharmaceuticals have signed an exclusive license and supply agreement for the distribution of Rolontis® (Eflapegrastim)); an Innovative Biologic for the Treatment of Chemotherapy-induced Neutropenia in Saudi Arabia and MENA region.
This strategic collaboration with Hanmi underscores Tabuk’s commitment to expanding access to advanced biologic and specialty medicines in line with Saudi Arabia’s Vision contributing to improved health outcomes and the long-term advancement of regional healthcare. .
